7 results
Oral anticoagulant dosing and bridging for VTE

- Dr. Joseph Shatzel @Clotmaster 

#VTE #DOAC #Bridging #Dosing #Oral
Oral anticoagulant ... Clotmaster #VTE #DOAC ... #Anticoagulation ... Dabigatran #Apixaban #Rivaroxaban ... #Pharmacology #Hematology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
stratification algorithm ... , edoxaban and rivaroxaban ... controlled trial ... #Anticoagulation ... #Management #Hematology
Anticoagulant Bridging

 • Switching from LMWH
 • Switching from UFH
 • Switching from DOAC to Warfarin
Anticoagulant Bridging ... Switching from DOAC ... #Bridging #anticoagulation ... #pharmacology #management ... #hematology
Cardiac Valve Replacement - Anticoagulation INR Targets and Antiplatelet by Valve Type

Bioprosthetic valves require at least
utilize direct oral anticoagulants ... (DOACs) for bioprosthetic ... patients with chronic atrial ... #Management #Cardiology ... #INR #Target #DOAC
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
Treatment algorithm ... DOAC, direct oral ... #DOAC #VTE #Malignancy ... #Anticoagulation ... #Management #Hematology
Atrial Fibrillation (A-Fib) Summary

Symptoms:
• Palpitations, light-headedness, dizziness, dyspnea, exercise intolerance, chest pain, near-syncope, syncope.

Why?
Cardiac:
	• Valvular heart
β-blocker or CCB Anticoagulation ... typically needed • DOACs ... Xa inhibitors (rivaroxaban ... AFib #diagnosis #management ... #cardiology
Anticoagulant Therapy after PCI (patients with AFib)
Dual-Therapy Preferred:
 • Triple therapy = increased bleeding
Anticoagulant Therapy ... due to use of DOAC ... patients in clinical trials ... Triple #therapy #anticoagulation ... #pharmacology #management